AeroClean’s Pūrgo™ Air Purifier Receives FDA Clearance for the Elimination of SARS-CoV-2

Provided By Globe Newswire

Last update: Dec 7, 2022

Additional Testing Being Performed to Confirm Elimination of Influenza and RSV

PALM BEACH GARDENS, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a leading air hygiene technology company, today announced that, the U.S. Food and Drug Administration (“FDA”) has granted AeroClean 510k clearance (K223328) to update its Pūrgo™ air purifier’s (“Pūrgo™”) indications for use to include the elimination of SARS-CoV-2, the RNA virus that causes COVID-19. The FDA has reviewed the laboratory performance data and confirmed the applicability of Pūrgo to remove SARS-CoV-2 from the air in indoor environments. The clearance adds SARS-CoV-2 to the list of microorganisms already cleared. As part of AeroClean’s ongoing commitment to improve Indoor Air Quality (“IAQ”) for a healthier and safer world, the Company has commenced additional efficacy testing on viruses that are known threats to health such as influenza and respiratory syncytial virus (RSV).